Health Information and Quality Authority (HIQA) develops national HTA guidelines to support decision-making in Ireland. In the first quarter of 2021, Health Information and Quality Authority published only one assessment of Extended Interval Screening by the Diabetic RetinaScreen Programme.
This report has provided an overview of the evidence pertaining to extending the screening interval for diabetic retinopathy from one to two years for those at low risk of diabetic retinopathy progression.
It was concluded that this interval appears to be safe and in line with international best practices. However, any planned changes to the national program would need to be accompanied by a significant communications campaign, including all relevant stakeholders, to address potential concerns.
The details of the published assessments can be found here.
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news).
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).